Related Experiment Video
Updated: Aug 13, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
[Statins in chronic renal disease]
Soraia R C Ferreira1, Aloísio M Rocha, José Francisco K Saraiva
1Faculdade de Medicina, PUC de Campinas.
Insights
Statins may protect kidney disease progression and reduce cardiovascular risks in renal failure patients. However, recent trials show mixed results, necessitating further research for specific patient groups.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Context:
- Chronic renal failure (CRF) is linked to dyslipidemia, including hypertriglyceridemia and low HDL-c.
- Patients with CRF face a significantly elevated risk of cardiovascular mortality (10-20 times higher).
Purpose:
- To evaluate the role of statins in managing cardiovascular risks and renal disease progression in patients with chronic kidney disease.
Summary:
- Clinical trials suggest statins may slow renal disease progression.
- Fluvastatin use after renal transplant correlated with reduced cardiovascular events.
- A recent atorvastatin study in diabetic hemodialysis patients did not show cardiovascular benefits.
Impact:
- Statins show potential in mitigating cardiovascular mortality in renal failure patients.
- The precise role of statins in specific CKD populations, like diabetic hemodialysis patients, requires further investigation through ongoing trials.
Abstract:
Hypertriglyceridemia and low HDL-c are common features in patients with chronic renal failure. Cardiovascular mortality is substantially increased in the presence of chronic renal disease (10-20 times higher). There is evidence from clinical trials with statins suggesting their protective role in the progression of renal disease. In addition, reduced rates of non-fatal myocardial infarction and cardiac mortality were seen after renal transplant in patients receiving fluvastatin. However, a recent study with atorvastatin failed to demonstrate reduction in cardiovascular morbidity and mortality among diabetic patients on hemodialysis therapy. Ongoing trials will define the precise role of statins in this subset of patients.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease IV: Nursing Management
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Chronic Kidney Disease II: Clinical Manifestations